Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Toshiyuki Onogawa"'
Autor:
Shigeki Nakamura, Takahiro Hirano, Toshiyuki Onogawa, Shuji Itoh, Ayako Hashimoto, Yoshitaka Yamamura, Kazumi Kondo, Toyoki Mori, Toshimi Kambe
Publikováno v:
Journal of Pharmacological Sciences, Vol 94, Iss 4, Pp 426-433 (2004)
We elucidated the pharmacological properties of a novel nonpeptide vasopressin V2-receptor agonist, OPC-51803 ((5R)-2-[1-(2-chloro-4-(1-pyrrolidinyl)benzoyl-2,3,4,5-tetra-hydro-1H-1-benzazepine-5-yl]-N-isopropylacetamide), via both in vitro binding e
Externí odkaz:
https://doaj.org/article/1f443f649afc4a158ca337bba93b564f
Autor:
Hidenori Ogawa, Hiroshi Yamashita, Toyoki Mori, Hisashi Miyamoto, Michiaki Tominaga, Yoshitaka Yamamura, Kazumi Kondo, Kenji Nakaya, Toshiyuki Onogawa, Shigeki Nakamura, Kazuyoshi Kitano, Michinori Tanaka
Publikováno v:
Bioorganic & Medicinal Chemistry. 7:1743-1754
We previously reported a series of benzazepine derivatives as orally active nonpeptide arginine vasopressin (AVP) V2 receptor antagonists. After the lead structure OPC-31260 was structurally evaluated and optimized, the introduction of the 7-Cl moiet
Autor:
Toshiyuki Onogawa, Michiaki Tominaga, Yoshihisa Yamada, Toyoki Mori, Tomihiko Chihara, Shigeki Nakamura, Yoshitaka Yamamura, Tatsuya Yamashita, Youichi Yabuuchi
Publikováno v:
Hypertension. 23:200-204
We studied the hypotensive effects of OPC-21268, an orally effective nonpeptide vasopressin V1 receptor antagonist, in spontaneously hypertensive rats (SHR) and stroke-prone SHR (SHRSP). OPC-21268 was given intravenously to conscious, freely moving S
Autor:
Toshiyuki Onogawa, Hiroyuki Fujiki, Nakayama Sunao, Yoshitaka Yamamura, Yuki Sakamoto, Shigeki Nakamura
Publikováno v:
Cardiovascular drugs and therapy. 25
We investigated the effects of tolvaptan, a vasopressin V(2)-receptor antagonist, on diuretic response and systemic and renal hemodynamic characteristics in conscious dogs with congestive heart failure (CHF). We also compared these effects with those
Autor:
Toshiyuki Onogawa, Hidenori Ogawa, Hisashi Miyamoto, Tomihiko Chihara, Toyoki Mori, Hiroshi Yamashita, Shigeki Nakamura, Michiaki Tominaga, Youichi Yabuuchi, Tatsuya Yamashita, Yoshitaka Yamamura, Tetsumi Hosokawa
Publikováno v:
British Journal of Pharmacology. 105:787-791
1. OPC-31260, a benzazepine derivative, has been studied for its ability to antagonize the binding of arginine vasopressin (AVP) to receptors in rat liver (V1) and kidney (V2) plasma membranes, for antagonism of the antidiuretic action of AVP in alco
Autor:
Toyoki Mori, Shizuo Kinoshita, Yoshitaka Yamamura, Hiroyuki Fujiki, Toshiyuki Onogawa, Nakayama Sunao, Toshiki Miyazaki, Shigeki Nakamura
Publikováno v:
Endocrinology. 146(7)
The therapeutic efficacy of tolvaptan (OPC-41061), a potent, selective nonpeptide vasopressin V2 receptor antagonist, on acute and chronic severe hyponatremia was assessed in rats. Experiments were designed to demonstrate the efficacy of tolvaptan re
Autor:
Toyoki Mori, Shigeki Nakamura, Kazumi Kondo, Ayako Hashimoto, Shuji Itoh, Yoshitaka Yamamura, Takahiro Hirano, Toshiyuki Onogawa, Toshimi Kambe
Publikováno v:
Journal of Pharmacological Sciences, Vol 94, Iss 4, Pp 426-433 (2004)
We elucidated the pharmacological properties of a novel nonpeptide vasopressin V2-receptor agonist, OPC-51803 ((5R)-2-[1-(2-chloro-4-(1-pyrrolidinyl)benzoyl-2,3,4,5-tetra-hydro-1H-1-benzazepine-5-yl]-N-isopropylacetamide), via both in vitro binding e
Autor:
Tomihiko Chihara, Toshiyuki Onogawa, Toyoki Mori, Tatsuya Yamashita, Youichi Yabuuchi, Yoshitaka Yamamura, Shigeki Nakamura, Michiaki Tominaga
Publikováno v:
Japanese journal of pharmacology. 68(3)
We studied the antagonistic actions of OPC-21268 (1-{1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl}-3, 4-dihydro-2(1H)-quinolinone) on the arginine vasopressin (AVP)-induced vasoconstrictor response in the spinally-anesthetized dog. OPC-21268 at d
Autor:
T Kumada, Masashi Kambayashi, Noboru Ishikawa, Yoshitaka Yamamura, Fujimasa Kohno, Toshiyuki Onogawa, Shigetake Sasayama
Publikováno v:
Journal of the American College of Cardiology. 25(2)
We assessed the long-term effects of oral vasopressin V1 antagonist, OPC-21268 (1-1-[4-(3-acetylaminopropoxy)benzoyl]-4-piperidyl-3.4-dihydro-2(1H)quinolinone) in conscious dogs with regional myocardial damage by repetitive DC-shocks. Methods Study d
Autor:
Toshiyuki Onogawa, Yoshitaka Yamamura, Kazumi Kondo, Toyoki Mori, Michiaki Tominaga, Shigeki Nakamura, Youichi Yabuuchi, Hidenori Ogawa, Tomihiko Chihara
Publikováno v:
Science (New York, N.Y.). 252(5005)
An orally effective, nonpeptide, vasopressin V1 receptor antagonist, OPC-21268, has been identified. This compound selectively antagonized binding to the V1 subtype of the vasopressin receptor in a competitive manner. In vivo, the compound acted as a